CIK 0002114044 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Hemab Therapeutics Holdings, Inc.
Sign in to watch- Ticker
- COAG
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 414241952
- Phone
- 45 2138 7627
- Business address
- 101 MAIN STREET, SUITE 1220, CAMBRIDGE, MA, 02142
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-05-04 | RA CAPITAL MANAGEMENT, L.P. Director | Conversion | +3,607,846 | 3,607,846 | ||
| 2026-05-04 | RA CAPITAL MANAGEMENT, L.P. Director | Conversion | +1,009,052 | 1,009,052 | ||
| 2026-05-04 | RA CAPITAL MANAGEMENT, L.P. Director | Conversion | +221,188 | 221,188 | ||
| 2026-05-04 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | +2,541,250 | $18.00 | $45.7M | 6,149,096 |
| 2026-05-04 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | +133,750 | $18.00 | $2.4M | 354,938 |
| 2026-05-04 | RA CAPITAL MANAGEMENT, L.P. Director | Conversion · Series A Preferred Stock | −64,680 | 0 | ||
| 2026-05-04 | RA CAPITAL MANAGEMENT, L.P. Director | Conversion · Series A Preferred Stock | −27,720 | 0 | ||
| 2026-05-04 | RA CAPITAL MANAGEMENT, L.P. Director | Conversion · Series B Preferred Stock | −42,341 | 0 | ||
| 2026-05-04 | RA CAPITAL MANAGEMENT, L.P. Director | Conversion · Series B Preferred Stock | −18,146 | 0 | ||
| 2026-05-04 | RA CAPITAL MANAGEMENT, L.P. Director | Conversion · Series C Preferred Stock | −56,972 | 0 | ||
| 2026-05-04 | RA CAPITAL MANAGEMENT, L.P. Director | Conversion · Series C Preferred Stock | −10,054 | 0 | ||
| 2026-05-04 | MARAGANORE JOHN Director | Conversion | +17,974 | 17,974 | ||
| 2026-05-04 | MARAGANORE JOHN Director | Conversion | +17,974 | 35,948 | ||
| 2026-05-04 | MARAGANORE JOHN Director | Conversion · Series B Preferred Stock | −817 | 0 | ||
| 2026-05-04 | MARAGANORE JOHN Director | Conversion · Series C Preferred Stock | −817 | 0 | ||
| 2026-04-30 | Madigan Catherine Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +49,016 | 49,016 | ||
| 2026-04-30 | Behrndt-Eriksen Mads Nikolaj See Remarks | Grant or award · Stock Option (Right to Buy) | +49,016 | 49,016 | ||
| 2026-01-29 | MARAGANORE JOHN Director | Grant or award · Warrants (Right to Buy) | +107,338 | 107,338 | ||
| 2026-01-29 | Madigan Catherine Chief Medical Officer | Grant or award · Warrants (Right to Buy) | +145,134 | 145,134 | ||
| 2026-01-29 | Behrndt-Eriksen Mads Nikolaj See Remarks | Grant or award · Warrants (Right to Buy) | +195,206 | 195,206 |
Page 2 of 2 · 40 trades